To address these challenges, a novel therapeutic strategy employing a cationic liposome‐based biomimetic drug co‐delivery system, siPFKFB4/PRLPTX@RBCM‐cRGD, which simultaneously delivers paclitaxel and PFKFB4‐targeting small interfering RNA (siRNA) to SCLC cells and tissues is proposed. Here, PFKFB4 is linked to small cell lung carcinoma.